Biofrontera AG

Data from pivotal Phase III studies with BF-200 ALA introduced to US dermtologists - Seite 2

References 1. Szeimies et al., 2010. 2. Dirschka et al., 2012. 3. Reinhold et al, submitted.

About South Beach Symposium The South Beach Symposium has an audience of more than 550 attendees, with approximately 95% physicians in core specialties including Dermatology, Plastic Surgery, Ophthalmology and Facial Plastic Surgery. The Symposium features cutting edge educational sessions with non-overlapping CME tracks: the Masters of Pediatric Dermatology Symposium, the South Beach Clinical Dermatology Symposium, the South Beach Aesthetics Symposium and the Practice Management Symposium.

Ends

Enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer [phone] [e-mail] www.biofrontera.com

IR Germany: Brainwell Asset Solutions Jürgen Benker [phone]

Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs [phone]

IR UK: Seton Services Toni Vallen [phone]

Financial PR: Gable Communications John Bick / Justine James [phone] [phone]

About Biofrontera

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.



(end)

emitter: Biofrontera AG address: Hemmelrather Weg 201, 51377 Leverkusen country: Germany contact person: Investor & public relations phone: [phone] e-mail: [e-mail] website: www.biofrontera.com

ISIN(s): DE0006046113 (share) stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin

[ source: http://www.pressetext.com/news/20160211026 ]